CHARACTERIZATION OF A HIGHLY NEUTRALIZING SINGLE MONOCLONAL ANTIBODY TO BOTULINUM NEUROTOXIN TYPE A

Sébastien Brier¹, Christine Rasetti-Escargueil², Anne Wijkhuisen³, Stéphanie Simon³, Maud Marechal², Emmanuel Lemichez², Michel R. Popoff^{2*}

¹Biological NMR Technological Platform, Institut Pasteur, CNRS UMR3528, 75015 Paris, France

²Institut Pasteur, Toxines Bactériennes, CNRS ERL6002, 75015 Paris, France

³Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la santé, 91191 Gif-sur-Yvette, France

- Corresponding author popoff2m@gmail.com, Ph 33 643551035

ABSTRACT (228 mots)

Compared to conventional antisera strategies, monoclonal antibodies (mAbs) represent an alternative and safer way to treat botulism, a fatal flaccid paralysis due to botulinum neurotoxins (BoNTs). In addition, mAbs offer the advantage to be produced in a reproducible manner. We previously identified a unique and potent mouse mAb (TA12) targeting BoNT/A1 with high affinity and neutralizing activity. In this study, we characterized the molecular basis of TA12 neutralization by combining Hydrogen/Deuterium eXchange Mass Spectrometry (HDX-MS) with site directed mutagenesis and functional studies. We found that TA12 recognizes a conformational epitope located at the interface between the H_{CN} and H_{CC} subdomains of the BoNT/A1 receptor-binding domain (H_C). The TA12 binding interface shares common structural features with the ciA-C2 VHH epitope and lies on the face opposite recognized by ciA-C2 and the CR1/CR2 neutralizing mAbs. The single substitution of N1006 was sufficient to affect TA12 binding to H_C confirming the position of the epitope. We further uncovered that the TA12 epitope overlaps with the BoNT/A1 binding site for both the neuronal cell surface receptor synaptic vesicle glycoprotein 2 isoform C (SV2C) and the GT1b ganglioside. Hence, TA12 potently blocks the entry of BoNT/A1 into neurons by interfering simultaneously with the binding of SV2C and to a lower extent GT1b. Our study reveals the unique neutralisation

mechanism of TA12 and emphasizes on the potential of using single mAbs for the treatment of botulism type A.

Key Words

Botulinum neurotoxin; Botulism; Monoclonal antibody; Synaptic vesicle protein 2; GT1b, Mass spectrometry; Hydrogen-Deuterium eXchange; Epitope mapping

Running title

Potent neutralization of BoNT/A1 with a single mAb

Nonstandard abbreviations

BoNT, botulinum neurotoxin

L, light chain

H, heavy chain

H_C, half C-terminal H chain

H_N, half N-terminal H chain

SV2C, synaptic vesicle protein 2C

gSV2C, glycosylated SV2C

SNARE, soluble *N*-ethylmaleimide-sensitive-factor attachment protein receptor

mAb, monoclonal antibody

HDX-MS, Hydrogen/Deuterium eXchange Mass Spectrometry

TCEP, Tris(2-carboxylethyl)phosphine

EIA, enzyme immunoassay

LD, luminal domain

BSA, bovine serum albumin

AMC, anti-mouse Fc

TGY, trypticase-glucose-yeast extract

VHH, variable domain of heavy chain

MLD, mouse lethal dose

INTRODUCTION

Botulism is a rare but severe disease that results from botulinum neurotoxin (BoNT) intoxication. Naturally acquired botulism can develop in three main forms: foodborne BoNT intoxication, intestinal colonization by BoNT-producing clostridium (infant botulism and more rarely botulism by intestinal colonization in adults), or wound botulism. Among the seven different BoNT toxinotypes, BoNT/A is the most potent toxin with a lethal dose for human estimated at ~1 ng/kg by parenteral route (1, 2). BoNTs and specially the BoNT/A toxinotype are therefore classified by the Centers for Diseases Control and Prevention (CDC) among the six major bioterrorism agents (category A) (3). BoNT/A is a ~1296 residues long protein that is proteolytically processed into a light (L) and a heavy chain (H) linked by a single disulfide bond. The L chain contains the intracellularly active enzymatic site that specifically cleaves neuronal members of the *N*-ethylmaleimide sensitive factor attachment protein receptors (SNAREs) complex required for the release of acetylcholine. The C-terminal H chain (H_C) recognizes both the intraluminal loop of the synaptic vesicle glycoprotein 2C (SV2C) and GT1b/GD1a gangliosides as functional dual receptors on neuronal cells. Finally, the N-terminal H domain (H_N) is involved in the translocation of the L chain from endocytic vesicles into the cytosol of neuronal cell targets (4-11).

Antitoxin serotherapies are currently the only specific and available treatments for botulism. The clinical benefit and effectiveness of such therapies remain however linked to their use at the early onset of the disease *only*. The equine antitoxin therapy composed of polyclonal IgG antibodies is the most available treatment although it is often associated to hypersensitivity reactions including serum sickness and cardiac arrest (12, 13). Human botulism-immune globulins from vaccinated donors have been developed notably for the treatment of infant botulism (14). The first one—BabyBIG, is supplied by the California Department of Public Health, but with limited stock. This formulation has been recently discontinued and will be replaced with a new formulation currently under clinical development (15). Recently, the safety of a new cocktail composed of three humanized mAbs (XOMA 3B) engineered to neutralize BoNT/A subclasses has been evaluated and confirmed in healthy volunteers (16). The European AntiBotABE Program has allowed the isolation of recombinant humanized antibodies neutralizing BoNT/A, B and E. Protective antibody combinations against BoNT/A and BoNT/B showed cross-neutralization of both BoNT/A1 and A2 as well as BoNT/B1 and B2, respectively (17).

Monoclonal antibodies (mAbs) represent therefore a promising alternative strategy to treat botulism with the advantage of being better tolerated by patients and produced in a more

reproducible and safer way than animal hyperimmune serum. Various murine or humanized mAbs raised against whole BoNTs or BoNT subdomains have been evaluated for their neutralizing potency and their possible therapeutic use (review in (17, 18)). Most often, efficient toxin neutralization requires a combination of several mAbs. For example, the association of three mAbs has been reported to neutralize BoNT/A, BoNT/E, or BoNT/F, respectively (19-21). Recently, a single anti-BoNT/A tri-epitopic mAb with equivalent binding and neutralization potency than three distinct mAbs has been generated (22). The use of a single mAb as alternative therapeutic antitoxin agent appears therefore promising and offers the advantage to simplify the process of development and to reduce the cost of production.

We previously reported a potent neutralizing murine mAb (named TA12) generated against the C-terminal domain of the BoNT/A1 heavy chain (H_CA1) (23, 24). In this study, we focused on the structural characterization of the TA12:H_CA1 complex by Hydrogen/Deuterium eXchange Mass Spectrometry (HDX-MS) approach combined with site directed mutagenesis and functional assays (25, 26). We report that TA12 targets a conformational epitope on H_CA1 located at the junction between the H_{CC} and the H_{CN} subdomains. The TA12 epitope overlaps with both the SV2C cell receptor and the GT1b binding sites, hence perturbing the dual-receptor binding process required for the entry of BoNT/A1 into neuronal cells.

MATERIALS AND METHODS

Biological reagents

mAb TA12 was prepared and affinity purified on protein A beads (Prosep-A High capacity, Millipore, Billerica, USA) as previously described (27).

Recombinant H_C of BoNT/A1 (H_CA1), corresponding to the receptor binding domain of BoNT/A1 was prepared as previously described (28). DNAs encoding H_C of BoNT/A subtypes were PCR amplified with primers and *C. botulinum* genomic DNA (**Extended Table 1**) and cloned into pET28a. Recombinant H_C containing N-terminal 6xHis-tag were produced and purified as previously described (28). Primers used to generate H_CA1 mutants are indicated in **Extended Table 2**.

cDNA encoding the human intraluminal SV2C fragment L4 (amino acid 454 to 579, hereafter named SV2C-LD) was PCR amplified as previously described (29). Briefly, DNA encoding the amino acids 454 to 579 of human SV2C was PCR amplified with primers P1415 (5'- GGATCCTTCCCTGATGTCATTAAACCTCTG-3') and P1416 (5'- GAATTCCTAGTAGGCACTATAGTCATCATCAAA-3') adding *Bam*HI and *Eco*RI restriction sites, respectively, and was cloned into pGEX-2T at the corresponding restriction

sites. The construction was verified by DNA sequencing. The fusion protein (41 kDa) contains N-terminal GST and C-terminal SV2C-LD linked by Gly-Ser resulting from the *Bam*HI site. The recombinant plasmid was cloned into *E. coli* BL21 DE3 and the resulting bacterial strain was grown in LB medium containing ampicillin (100 µg/ml). The culture was induced with IPTG (0.2 mM) and further grown at 18°C for 18 h. The bacterial cells were washed with distilled water, suspended in 50 mM Tris, 150 mM NaCl, 10 mM MgCl₂, 1 mM dithiotreitol, 0.1% Tween20 containing complete protease inhibitor cocktail EDTA free (Roche, France), and lysed by ultrasonication. The lysate was incubated with Glutathione-Sepharose-4B beads (GE Healthcare) for 1 h at 4°C. The beads were washed three times with the same buffer and a 50% suspension in the same buffer was used for the pull-down assays.

For HDX-MS experiments, 6His-tag-SV2C-LD was used. The PCR amplified DNA encoding SV2C-LD was cloned into pET28 vector at the *Bam*HI-*Eco*RI site. The recombinant N-terminal 6His-tag-SV2C-LD protein was produced in *E. coli* BL21 DE3 and purified on a Talon metal affinity matrix (Clontech) equilibrated in 10 mM Tris, 150 mM NaCl, 10 mM imidazole, 10 mM TCEP, pH 7.5. The recombinant protein was eluted with the same buffer supplemented with 100 mM imidazole and dialyzed against the same buffer without imidazole.

Affinity determination of mAb TA12

The affinities of mAb TA12 for different recombinant HcBoNT isoforms were determined by Bio-layer Interferometry using the ForteBio system (Pall Laboratory). mAb TA12 prepared at 10 µg/mL in EIA (enzyme immunoassay) buffer (0.1 M phosphate buffer, pH 7.4, 0.15 M NaCl, 0.1% BSA, and 0.01% sodium azide) + 0.02% Tween 20 (Sigma) was dispensed in 96-well microplates at a volume of 200 µL per well. The same concentration occupied 8 vertical wells. In other wells, recombinant HcBoNT proteins were dispensed at 8 titrated concentrations (between 100 and 0 nM depending on the protein). A glycine (Sigma, pH [1.4]) regeneration solution and EIA buffer + 0.02% Tween 20 for baseline stabilization and neutralization was also prepared. The plate was agitated at 1000 rpm over the entire course of the experiment. Prior to the binding measurements, the anti-mouse Fc (AMC) sensors tips were hydrated in EIA buffer + 0.02% tween 20. The sensor tips were then transferred to the EIA buffer + 0.02% Tween 20 for the baseline, then for 300 sec into wells containing mAb for loading step. After baseline step in EIA buffer + 0.02% Tween 20 for 60 sec, the binding kinetics were measured by dipping the mAb-coated sensors into the wells containing recombinant HcBoNT at varying concentrations. The binding interactions were monitoring over a 900 sec associated period and followed by a 900 sec dissociation period in the wells containing EIA buffer +0.02 % Tween

20. Between each binding cycle, the AMC sensors tips were regenerated with wells containing glycine and neutralized in the EIA buffer + 0.02% tween 20. The equilibrium dissociation constant (K_D) was calculated using the ratio between the dissociation rate constant (k_{off}) and the association rate constant (k_{on}), obtained with a global Langmuir 1:1 fit (Octet Data Analysis software, vHT.10).

GST pull down assay

Recombinant SV2C-LD immobilized on glutathione-Sepharose-4B matrix (GE healthcare, France) (30 μ L of 50% bead suspension) was incubated for 90 min at 4°C with HcA1 solutions prepared with or without mAb TA12 in 50 mM Tris buffer, 150 mM NaCl, 10 mM $MgCl_2$, 2 mM dithiothreitol, 0.1% Tween 20, pH 7.5, supplemented with antiproteases (protease inhibitor cocktail EDTA free, Roche Diagnostics, Germany) (final volume 400 μ L). HcA1:TA12 solutions were pre-incubated for 15 min at room temperature before use. Beads were collected by centrifugation and washed three times with the same buffer. Washed pellets were suspended in SDS/2-mercaptoethanol sample buffer for 2 min at 95°C and analyzed by SDS-PAGE. Proteins were stained by Coomassie blue.

Ganglioside binding assay

Binding of HcA1 to the GT1b ganglioside was assessed in a solid phase assay as previously described (30-32). Briefly, bovine brain GT1b (Calbiochem, France) stored in dimethyl sulfoxide (20 mg/mL) at -20°C was diluted in methanol and applied overnight to 96-well plates (Corning-Costar, France) at 2 μ g per well. Methanol was evaporated at room temperature and the plates were washed three times with phosphate-buffered saline containing 0.05 % Tween 20 (Sigma, France) (PBST). Plates were blocked with 5% non-fat skim milk in PBST for 1 h at room temperature and washed with PBST. HcA1 was then dispensed (10 nM/well in PBS) in the control wells and incubated for 2 h at 4°C. For competition with mAb TA12, HcA1 (10 nM) was incubated with various concentrations of TA12 in 100 μ L PBS for 15 min at room temperature prior being applied to GT1b coated wells for 2 h at 4°C. After washing with PBST, bound HcA1 was detected with rabbit anti-HcA1 (1:10,000) (29) and horse radish peroxidase (HRP) goat anti-rabbit immunoglobulin IgG (1:3,000) (Invitrogen, France). Ortho phenyldiamine (Sigma, France) was used as substrate (1 mg/mL in citrate buffer pH 4.5 containing H_2O_2), and the reaction was stopped with HCl 3 M (50 μ L/well). The extinction was measured at 490 nm and 650 nm as reference.

Neutralizing activity

BoNTs were prepared from *C. botulinum* cultures in TGY (trypticase-glucose-yeast extract) medium for four days under anaerobic conditions at 37°C as previously described (33). Briefly, the cultures were acidified at pH 3.5 with sulfuric acid, centrifuged at 10,000 x g for 15 min at 4°C, washed with distilled water, and the BoNT complexes were extracted three times with 0.2 M phosphate buffer pH 6.3. BoNT complexes were precipitated with 65% ammonium sulfate saturation and then dialyzed against 50 mM phosphate buffer, pH 6.3 containing 0.2% gelatin (PB-G).

Mouse protection assay was performed with male Swiss mice (Charles River) weighing 20-22 g as previously described (34). Variable amounts of TA12 were incubated with 5 estimated mouse 50% lethal doses of either BoNT/A1, A2, A3, A5 or A7 in PB-G for 30 min at room temperature. The mixtures (0.5 mL) were then injected intraperitoneally into mice with control mice receiving BoNT alone. Mice were observed and any death was recorded every day during 4 days.

Ethic statements

All experiments were performed in accordance with French and European Community guidelines for laboratory animal handling. The protocols of experiments were approved by Institut Pasteur CETEA (Comité d'Ethique en Expérimentation Animale) with the agreement of laboratory animal use (N° 2013-0116) and by the Ministère de l'Education Nationale et de l'Enseignement Supérieur with the agreement 02026.02.

HDX-MS experiments

A summary of the HDX data containing the main experimental details is provided in **Extended Table 3** (35). Prior to initiating the labeling, the quality of each protein was assessed by SDS-PAGE and intact mass analysis (**Extended Figure 1**).

Sample preparation. For epitope mapping, H_CA1 was labeled in both the presence and absence of the mouse mAb TA12. The TA12: H_CA1 complex was formed by mixing 3 µL of H_CA1 (29 µM in buffer A: 10 mM Tris, 150 mM NaCl, pH 7.4) with 4.5 µL of mAb TA12 (27 µM in buffer A). Control samples (unbound H_CA1) were prepared in parallel by replacing TA12 with buffer A. After 1 h incubation at 20°C, the labeling was initiated by adding 67.5 µL of

deuterated buffer (10 mM Tris, 150 mM NaCl, pD 7.4; D₂O/H₂O ratio: 90/10%). Assuming a K_D value of ~20 pM (24) (and this study), ~100% of H_CA1 remains bound to TA12 during hydrogen exchange. Continuous labeling was performed at 20°C for $t = 0.16, 1, 5, 10, 30, 60$ and 120 min. Aliquots of 10 μ L (*i.e.*, 11.6 pmoles of H_CA1) were removed and quenched upon mixing with 50 μ L of an ice cold solution of 2% formic acid, 4M urea to decrease the pH to 2.5 (Final D₂O/H₂O ratio: 15/85%). Quenched samples were immediately snap frozen in liquid nitrogen and stored at -80°C until MS acquisition (less than 3 days).

An identical procedure was used to map the SV2C-LD interaction site on H_CA1. The SV2C-LD: H_CA1 complex was formed by mixing 3 μ L of H_CA1 (29 μ M in buffer A) with 4.5 μ L of SV2C-LD (22 μ M in buffer A supplemented with 10 mM TCEP). The labeling was performed in the presence of 1 mM TCEP at 20°C. Assuming a K_D value of 28 nM (6), 90.5% of H_CA1 remains bound to SV2C-LD during labeling.

Undeuterated H_CA1 samples were obtained following the same experimental procedure. A fully deuterated H_CA1 control was prepared in 10 mM Tris buffer, 150 mM NaCl, 8 M urea-d₄, pD 7.4 (D₂O/H₂O ratio: 90/10%), incubated overnight at 20°C and processed as described above. All samples were prepared in triplicate for each time point and condition (independent technical replicate).

Data acquisition. Quenched samples were rapidly thawed and injected onto a nanoACQUITY UPLC M-Class system (Waters Corporation, Milford, MA) equipped with a HDX manager maintained at 0°C to minimize back-exchange. Labeled samples (9.7 pmol of H_CA1 either alone or with 13.5/11 pmol of TA12/SV2C-LD) were digested using an in-house packed cartridge (2.0 x 20 mm, 63 μ L bed volume) of immobilized pepsin beads (Thermo Scientific, Rockford, IL) for 2 min at 20°C. Peptides were directly trapped and desalted onto a C18 Trap column (VanGuard BEH 1.7 μ m, 2.1 x 5 mm, Waters Corporation, Milford, MA) at a flow rate of 100 μ L/min (0.15% formic acid) and separated by a 10 min linear gradient of 5-40% acetonitrile at 40 μ L/min using an ACQUITY UPLC BEH C18 analytical column (1.7 μ m, 1 x 100 mm, Waters Corporation, Milford, MA). After each run, the pepsin column was manually cleaned with two consecutive injections of 1% formic acid, 5% acetonitrile, 1.5 M guanidinium chloride, pH 1.7. Blank injections were performed between each run to confirm the absence of carry-over. Mass spectra were acquired in resolution and positive mode (m/z 50-2000) on a Synapt G2-Si HDMS mass spectrometer (Waters Corporation, Milford, MA) equipped with a standard ESI source and lock-mass correction. Peptic peptides were identified in undeuterated

samples by a combination of data independent acquisition (MS^E) and exact mass measurement (below 5.0 ppm mass error) using the same chromatographic conditions than for the deuterated samples.

Data processing. The initial peptide map of HcA1 was generated by database searching in ProteinLynX Global server 3.0 (Waters corporation, Milford, MA) using the following processing and workflow parameters: low and elevated intensity thresholds set to 100.0 and 50.0 counts; intensity threshold sets to 750.0 counts; automatic peptide and fragment tolerance; non-specific primary digest reagent; false discovery rate sets to 4%. Each fragmentation spectrum was manually inspected for assignment confirmation. The peptide map was refined in DynamX 3.0 (Waters corporation, Milford, MA) using the following Import PLGS results filter: minimum intensity = 1500; minimum products per amino acid = 0.4; minimum score = 6.8; maximum MH^+ error (ppm) = 5; file threshold = 2.

DynamX 3.0 was used to extract the centroid masses of all peptides selected for HDX-MS analyses. Only one unique charge state was considered per peptide and no back-exchange correction was performed. HDX results are reported as relative deuterium exchange level expressed in either mass unit or fractional exchange. Fractional exchange data were calculated by dividing the experimental uptake value by the theoretically maximum number of exchangeable backbone amide hydrogens that could be replaced into each peptide in 90% excess deuterium. MEMHDX (36) was used to visualize and statistically validate the HDX data (Wald test, false discovery rate of 5%).

The presence of bimodal m/z envelopes (i.e., EX1 behavior) was determined by visually inspecting the shape of the isotopic distribution for all peptides. HX-Express2 software was used to extract the uptake value of bimodal m/z envelopes using a Double-Gaussian fitting (37).

RESULTS

TA12 efficiently neutralizes BoNT/A1

BoNT/A is divided into 8 distinct subtypes (BoNT/A1 to BoNT/A8) according to their amino acid sequence variations ranging from 2.9 % to 15.6 % (1). Although the BoNT/A toxinotype is defined by its neutralization with polyclonal anti-BoNT/A antibodies, each subtype can be distinctly neutralized by individual mAbs (1). We recorded that TA12 efficiently neutralized BoNT/A1 and displayed an inhibitory spectrum on BoNT/A subtypes A2, A3, and A7 (**Table 1**) (23). However, it showed a weak neutralizing activity against BoNT/A5 (**Table 1**). Taken together, these results confirm that TA12 is a highly neutralizing mAb of the most

potent subtype BoNT/A1 with medium neutralizing activity against BoNT/A2 and A3 subtypes and low neutralizing activity against BoNT/A5 (38, 39).

TA12 binding affinity to BoNT/A subtypes

TA12 binding affinity to the H_C domain of different BoNT/A subtypes was determined by Bio-Layer Interferometry. The binding affinity of TA12 was very high for H_CA1, H_CA2, and H_CA3 with K_D values in the low pM range (i.e., < 100 pM; **Table 2**) in good agreement with previous data obtained for H_CA1 using Biacore instrument (24). The TA12 affinity was slightly lower with H_CA2 and significantly reduced with H_CA4, H_CA5, and H_CA7 with K_D values in the low nM range. These differences in K_D mainly result from faster dissociation rate values for H_CA2, H_CA4, H_CA5, and H_CA7 as compared to H_CA1. Indeed, TA12 interacts with the H_C domain of the different BoNT/A subtypes with similar on-rates values (**Table 2**). Consistent with the protection of TA12 on BoNT/A subtypes, TA12 binds BoNT/A H_C domains with maximal affinities for BoNT/A1, A2, and A3. These results reveal that low picomolar affinities for the H_C domain are required to achieve maximal TA12 neutralizing power in the mouse lethality assay.

TA12 recognizes a conformational epitope at the junction between the H_{CC} and the H_{CN} subdomains of H_CA1

To better understand the mechanism underlying BoNT/A1 neutralization by TA12, the free and TA12-bound state of H_CA1 were subjected to HDX-MS analysis. The quench and pepsin digestions were first optimized to generate a peptide map with high sequence coverage and peptide redundancy. Urea was included in the quench buffer to favor the dissociation of the TA12: H_CA1 complex and increase the accessibility of both proteins to pepsin during the digestion step. A total of 98 unique peptides covering 85.2% of the H_CA1 sequence were confidently identified, of which 62 were selected for HDX-MS (**Extended Figure 2**). Overlapping peptides were only used to increase the spatial resolution when their back-exchange values were similar (i.e., < 10%; **Extended file HDX.xls**).

The binding of TA12 reduces the solvent accessibility of 12 peptides covering six distinct regions within H_CA1 (**Figure 1A, Extended Figure 3**). The main decreases in solvent accessibility occur in region 2 (peptide 1005-1016; loop β31-β32, β32), in region 4 (peptides 1114-1134, 1115-1134, 1116-1134 and 1117-1134; loop-β38-loop), and in region 5 (peptides 1135-1144, 1135-1147 and 1148-1154; β39-loop-β40-loop-β41). Inspection of the different

overlapping peptides in regions 2 and 4 reveals that the reduction of solvent accessibility is restricted to segments 1005-1009 and 1116-1124. In addition, a slight but statistically significant reduction in solvent accessibility was observed in region 1 (peptides 946-955, 946-958 and 946-961; loop β 27- β 28) and in region 6 (peptide 1250-1261; β 49-loop) (**Figure 1A and Extended Figure 4A**).

As shown in **Figure 1B**, TA12 binds H_CA1 at the junction between the N-terminal lectin subdomain (H_{CN}) and the C-terminal trefoil subdomain (H_{CC}). The TA12 epitope appears conformational and mainly formed by the β 27- β 28 and β 31- β 32 loops of H_{CN} and by the structural elements β 38 to β 41, β 49 and the β 37- β 38, β 39- β 40, β 40- β 41 and β 49- β 50 loops of H_{CC}. Interestingly, the HDX-MS defined TA12 epitope contains elements identified as important for the binding of both the SV2C luminal domain (SV2C-LD) and the GT1b ganglioside (**Figure 1B, regions 4, 5 and 6**). Indeed, the SV2C-LD binding site has been characterized in the H_{CN}-H_{CC} interface and the ganglioside binding pocket in the C-terminal part of H_{CC} (Glu1203-Gly1279 with Tyr1117 and Phe1252 playing a critical role) (6, 9, 40). Finally, TA12 also increases the deuterium uptake in region 3 (peptide 1017-1035; β 32-loop- β 33) in the lectin subdomain (**Figures 1A, 1B**). Upon complex formation, the isotopic profile of peptide 1017-1035 adopts a bimodal distribution characterized by a low and high m/z protein population (**Figure 1C**). Bimodal isotopic patterns result from cooperative exchanges (also known as EX1 regime) and are very rare in proteins under physiological conditions. Several experimental factors, such as carry-over or abnormal gas-phase back-exchange are known to generate false EX1 signatures. To rule out these possibilities, a blank was acquired between each injection and the pepsin column was carefully washed after each run. In addition, specific settings were applied on the mass spectrometer (source and ion transfer) to prevent gas-phase deuterium loss (41). We are therefore confident that the bimodal pattern observed with peptide 1017-1035 is not an experimental artefact but a true change in dynamics imposed by the binding of TA12. To extract the deuterium uptake level of the low and high m/z protein populations, the bimodal isotopic envelop was fitted with two Gaussians. The low m/z population showed no difference in deuterium uptake compared to free H_CA1 (**Figure 1C**). The high m/z population however displayed an evident and constant increase in deuterium uptake over time, with the incorporation of four additional deuteriums. This data confirms that segment 1017-1035 is destabilized in the complex.

Taken together, these data reveal that TA12 targets a conformational epitope located at the junction between the H_{CN} and H_{CC} subdomains that overlaps with the the SV2C-LD and the

GT1b binding site. The formation of the complex triggers a conformational change in the H_{CN} domain that was not observed with the two previously described neutralizing antibodies ciA-C2 and CR1 (see discussion) (42-45).

TA12 prevents BoNT/A1 interaction with SV2C-LD

The HDX-defined TA12 epitope overlaps with the SV2C-LD and the GT1b binding sites identified by X-ray crystallography (6, 40). SV2C-LD and GT1b both correspond to the neuronal cell surface receptors used by BoNT/A to efficiently and specifically enter neurons via a synergetic dual-binding process (8, 46-48). Based on this observation, we hypothesized that TA12 binding might interfere with the interaction of both SV2C-LD and GT1b.

We first focused our attention on the H_CA1:SV2C-LD interaction. The deuterium uptake profil of H_CA1 was monitored in the SV2C-LD:H_CA1 complex and compared to the one obtained in the presence of TA12. The binding of SV2C-LD induced several statistically significant changes (Wald test, $p < 0.05$) in deuterium uptake in H_CA1 (**Figure 2A; Extended Figures 4B, 5**). As observed in the H_CA1:TA12 complex, major reductions were observed in region 2 of the H_{CC} domain (peptides 1145-1154 and 1148-1154, region 5 in **Figure 1**) covering loops β 39- β 40 and β 40- β 41. Region 2 corresponds to the main SV2C-LD interaction site identified by X-ray crystallography and contains critical residues for binding such as T1145 and T1146 (**Figures 2B**) (6, 10). Therefore, these data confirm that TA12 and SV2C both target a common binding region on H_CA1 (Compare **Figures 1A, 1B and 2A, 2B**). Two additional regions surrounding residues 1145-1154, namely region 1 (peptides 946-955, 946-958 and 946-961) in the H_{CN} domain and region 3 (peptides 1282-1296, 1283-1296, 1284-1296 and 1285-1296) in the C-terminal part of H_{CC}, also display minor but statistically significant reductions in uptake upon complex formation. Region 3 contains several overlapping peptides with similar back-exchange values (**Extended file HDX.xls**) allowing to confine the effects of SV2C-LD binding to segment 1285-1296 *only*. This segment contains residue R1294 involved in the interaction and the binding specificity with SV2C-LD. Finally, although region 1 is very close to the main SV2C-LD interaction site (i.e., region 2), this latter was not identified as part of the SV2C-LD binding interface by X-ray crystallography (**Figure 2B**). Based on this observation, the slight decrease in solvent accessibility observed in 946-961 might be attributed to a change in dynamics rather than a masking effect.

We next performed *in vitro* experiments to analyze the interference of TA12 on the binding of recombinant H_CA1 to SV2C-LD immobilized on glutathione-Sepharose 4B beads. As shown in **Figure 2C**, H_CA1 binding to immobilized SV2C-LD was prevented in a TA12 dose-

dependent manner. More than 90% inhibition of binding was obtained at an equimolar ratio between TA12 and H_CA1. These results confirm that TA12 prevents the formation of the toxin/receptor complex via direct interaction with H_CA1. Thus, as observed with the neutralizing ciA-C2 VHH, TA12 blocks the entry of BoNT/A1 into neuronal cells by targeting one critical area of the toxin-cell receptor interface.

TA12 affects H_CA1 binding to GT1b

We next focused our attention on the H_CA1:GT1b interaction. Our HDX-MS data shows that TA12 affects the solvent accessibility of elements involved in the GT1b-binding site (**Figure 3A**). Region 1116-1124 contains residue Y1117 which directly coordinates GT1b through hydrogen bondings with sialic acid 5 (Sia5); residue F1252 in region 1250-1252 also hydrogen bonds to galactose 4 (Gal4) of the GT1b ganglioside (40). Compared to SV2C-LD, GT1b only shares a limited overlapping binding area with TA12 on H_CA1 (**Figure 3A**). Therefore, TA12 is not expected to directly compete with GT1b binding on H_CA1 as observed with SV2C-LD but rather to affect the H_CA1:GT1b interaction mainly through steric clashes.

To determine the effects of TA12 on H_CA1 binding to GT1b, an inhibition binding assay was performed using GT1b coated on plastic plate and incubated with H_CA1 either alone or in the presence of TA12. As shown in Figure 3B, increased concentrations of TA12 result in inhibition of H_CA1 binding to GT1b. Complete inhibition of H_CA1 binding to GT1b was achieved at a much higher TA12/H_CA1 molar ratio compared to SV2C-LD (10:1 for GT1b; 1:1 for SV2C-LD), hence suggesting that TA12 mainly causes indirect interferences with GT1b. Altogether, these data confirm that TA12 is also able to interfere with H_CA1 binding to GT1b albeit with a lower efficiency compared to the binding inhibition of H_CA1 to SV2C-LD.

Residue N1006 is important for TA12 binding.

Although TA12 recognizes the H_C domain of BoNT/A subtypes with high affinity (i.e., in the low pM-nM range; **Table 2**), the efficiency of neutralization appears subtype dependent. The quantity of TA12 required to neutralize 50% of the activity of both BoNT/A5 and A7 appears 400- and 40-fold higher than for BoNT/A1, respectively (**Table 1**). Interestingly, the H_C domain of BoNT/A1 shares respectively 94.1 and 91.7% sequence identity with H_CA5 and H_CA7, suggesting that small variations in the primary sequence are sufficient to explain the difference of neutralizing potency by TA12. To test this hypothesis, specific residues mainly positioned within the HDX-MS defined TA12 epitope where major changes in deuterium uptake occur upon binding were selected for substitution (**Extended Figure 6**). Four distinct

residues of H_CA1 including N1006 (region 2, **Figure 1**), and V1143, M1144 and R1156 (region 5, **Figure 1**) were replaced by the corresponding residues found in H_CA5 or H_CA7. The modified residues correspond to natural H_C variants and their mutation is therefore not expected to cause any local secondary structural changes on H_CA1. The substitution of V1143 alone or in combination with M1144 and R1156 showed no significant effect on TA12 binding (**Table 2**). By contrast, the substitution of N1006 with alanine strongly affects the binding of TA12 to H_CA1 with a 280-fold reduction in affinity compared to wild type (**Table 2**) confirming the importance of N1006 in complex formation.

DISCUSSION

Neutralizing antibodies against BoNT represent the only available antidote against botulism considering that vaccination is not an appropriate strategy due to the expanding therapeutic applications of BoNTs. Although equine anti-BoNT polyclonal sera are able to efficiently neutralize all seven known BoNT toxinotypes, their use can cause dramatic side effects (13, 49-53). Alternative therapeutic antitoxin approaches, such as mAbs or peptide inhibitors (6), are currently explored to reduce the risks of serum sickness and cardiac arrest. Human anti-BoNT immune globulins obtained from vaccinated donors have been developed for the treatment of infant botulism, but their production is not easily scalable (14). Recombinant mAbs and more specially recombinant humanized mAbs represent a promising and safer alternative strategy for botulism treatment. Their production is highly reproducible compared to animal hyperimmune sera thereby preventing batch to batch variations in antibody affinity (50). Over the last decade, several neutralizing mAbs against the distinct BoNT types have been generated (17, 18, 54). However, mAbs are specific of single epitopes *only* and extended protective coverage most often requires the combination of several mAbs. For example, the association of three distinct mAbs targeting non-overlapping epitopes of BoNT/A was found to be highly protective, whereas each single mAb showed no significant protection. Moreover, the three mAb in combination induced a 90-fold greater neutralizing potency of BoNT/A than human hyperimmune globulins (21). Although effective to treat botulism, the association of several mAbs introduces unique development and manufacturing challenges for clinical application. Recently, a single tri-epitopic IgG1-based mAb (TeAb) containing the binding sites of three individual anti-BoNT/A1 mAbs was engineered (22). TeAb was found to be much more potent in mouse-neutralization assay than any of the three single mAbs and almost as potent as the combination of the three individual mAbs against BoNT/A1. Though

the neutralization potency of TeAb against the other BoNT/A subtypes was not reported, this work highlights the potential of using single mAbs as alternative antitoxin solution (22).

In this study, we showed that the single TA12 mAb raised against H_CA1 is a potent inhibitor of the two most frequent subtypes involved in human botulism, namely A1 and A2 (55-57), but also A3. TA12 recognizes a conformational epitope mainly composed of solvent accessible loops located at the interface between the H_{CN} and the H_{CC} subdomain. The TA12 binding site overlaps with both the SV2C and the GT1b binding interfaces on H_CA1, causing interferences with the interaction of the two neuronal cell surface receptors used by BoNT/A to enter neurons. The strong neutralization potency of TA12 is therefore achieved by the synergetic and simultaneous inhibition of BoNT/A binding to GT1b and the peptide moiety of the SV2C luminal domain.

Two additional BoNT/A neutralizing antibodies have been reported to block the recognition of SV2C: the camelid single domain ciA-C2 antibody (42, 43) and the human monoclonal antibody CR1 currently in clinical trials (44, 45). The identification of the TA12 binding site provides a means to compare the different epitopes on H_CA1 and the neutralization mechanism of each antibody. All three antibodies target the same H_{CN}/H_{CC} junction, which was shown to elicit neutralizing antibodies against BoNT/A (28), but they adopt distinct orientation on H_CA1 (**Figure 4**). CR1 mainly occupies the SV2C glycan binding site on the H_{CN} subdomain. The CR1 epitope locates on the same H_CA1's face than the glycosylated SV2C (gSV2C) without sharing any overlapping peptide regions with gSV2C. The large size of CR1 and its close proximity with gSV2C are sufficient to generate local steric clashes between portions of CR1 and gSV2C, causing indirect interferences with gSV2C binding on H_CA1 (10, 45). The strong neutralizing potency of CR1 is therefore driven by two simultaneous blocking effects: an indirect effect with the SV2C peptides moieties and a direct effect through the occupation of the SV2C glycan binding site. As observed with CR1, ciA-C2 largely occupies the binding site for the SV2C glycan but it also interacts with a key region in the H_{CN} subdomain containing critical residues for gSV2C binding (**Figure 4**). Thus, ciA-C2 simultaneously inhibits both the protein- and the glycan- interactions between BoNT/A1 and gSV2C via direct blocking effects (43). The TA12 epitope shares common structural features with ciA-C2 as they both occupy the same gSV2C peptide binding site on H_CA1 and directly block gSV2C binding to BoNT/A (**Figure 4**). However, the TA12 binding interface lies on the face opposite recognized by both ciA-C2 and CR1, confirming that the H_{CN}/H_{CC} junction contains distinct antigenic regions able to elicit highly potent and unique BoNT/A neutralizing antibodies (28).

In contrast to both ciA-C2 and CR1, TA12 does not compete with the SV2C glycan but interferes with H_CA1 binding to GT1b.

The identification of the TA12 epitope on BoNT/A also provides a means to understand the variations in potency observed with the different H_CA subtypes (**Tables 1, 2**). The three main regions defining the TA12 epitope (i.e., I1005-D1009, Y1117-V1125, and L1136-L1154; **Extended Figure 6**) are relatively well conserved hence explaining the capabilities of TA12 to recognize all H_CA subtypes with high affinity. As previously reported, the antitoxin efficacy of antibodies largely depends on their binding affinity (42). Thereby, the highest TA12 binding affinities and neutralization potencies were obtained with subtypes A1, A3 and A2 whereas the lowest were observed with A5 and A7. TA12 binds A5 and A7 with affinity values comparable to both ciA-C2 and CR1 (i.e., in the low nanomolar range), and yet only poorly neutralizes BoNT/A5 in the mouse lethality assay. Low nanomolar K_D are therefore not sufficient because TA12 interferes simultaneously with the two BoNT/A cell binding partners. The unique neutralization mechanism of TA12 requires therefore low picomolar range affinity to prevent the displacement of the bound antibody from the toxin by either gSV2C, GT1b or both. We believe therefore that the differences in potency observed between H_CA subtypes are due to subtle amino-acid changes within the TA12 binding interface, resulting in lower K_D values, as we showed with residue 1006 in H_CA5. In addition, TA12 interferes on H_CA1 interaction with gangliosides. Albeit TA12 prevented H_CA1 binding to GT1b with lower efficiency compared to SV2C-LD, the cumulative effect of TA12 on binding to both types of H_CA1 cell receptors likely contributes to the highly efficient *in vivo* neutralization observed in mouse protection assay. To our knowledge, TA12 is the first antibody able to neutralize BoNT/A by simultaneously interfering with the binding to the two cell surface receptor types on motoneurons.

Acknowledgements

We thank UtechS MSBio of Institut Pasteur for the access to the HDX-MS instrumentation. The CACSICE Equipex ANR-11-EQPX-0008 is acknowledged.

Author contributions

M.R.P. designed the project. S.B., M.R.P, CRE, AW, SS, MM, designed and performed the experiments. S.B., M.R.P and CRE analyzed the data. S.B. and M.R.P. wrote the manuscript. All authors discussed and commented on the manuscript.

REFERENCES

1. Peck, M. W., Smith, T. J., Anniballi, F., Austin, J. W., Bano, L., Bradshaw, M., Cuervo, P., Cheng, L. W., Derman, Y., Dorner, B. G., Fisher, A., Hill, K. K., Kalb, S. R., Korkeala, H., Lindstrom, M., Lista, F., Luquez, C., Mazuet, C., Pirazzini, M., Popoff, M. R., Rossetto, O., Rummel, A., Sesardic, D., Singh, B. R., and Stringer, S. C. (2017) Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature. *Toxins (Basel)* **9**, 38
2. Poulain, B., and Popoff, M. R. (2019) Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic? *Toxins (Basel)*. **11**(1). toxins11010034. doi: 11010010.11013390/toxins11010034.
3. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., Lillibridge, S., Osterholm, M. T., O'Toole, T., Parker, G., Perl, T. M., Russell, P. K., Swardlow, D. L., and Tonat, K. (2001) Botulinum toxin as a biological weapon: medical and public health management. *JAMA* **285**, 1059-1070
4. Poulain, B., Molgo, J., and Popoff, M. R. (2015) Clostridial neurotoxins: from the cellular and molecular mode of action to their therapeutic use. In *The Comprehensive Sourcebook of Bacterial Protein Toxins* (Alouf, J., Ladant, D., and Popoff, M. R., eds) pp. 287-336, Elsevier, Amsterdam
5. Rossetto, O., Pirazzini, M., and Montecucco, C. (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. *Nat Rev Microbiol.* **12**, 535-549. doi: 10.1038/nrmicro3295.
6. Benoit, R. M., Frey, D., Hilbert, M., Kevenaar, J. T., Wieser, M. M., Stirnimann, C. U., McMillan, D., Ceska, T., Lebon, F., Jaussi, R., Steinmetz, M. O., Schertler, G. F., Hoogenraad, C. C., Capitani, G., and Kammerer, R. A. (2014) Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. *Nature*. **505**, 108-111. doi: 10.1038/nature12732.
7. Dong, M., Liu, H., Tepp, W. H., Johnson, E. A., Janz, R., and Chapman, E. R. (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. *Mol Biol Cell* **19**, 5226-5237

8. Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B., and Binz, T. (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. *FEBS Lett* **580**, 2011-2014
9. Rummel, A., Mahrhold, S., Bigalke, H., and Binz, T. (2004) The H_{cc}-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. *Mol. Microbiol.* **51**, 631-643
10. Yao, G., Zhang, S., Mahrhold, S., Lam, K. H., Stern, D., Bagramyan, K., Perry, K., Kalkum, M., Rummel, A., Dong, M., and Jin, R. (2016) N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. *Nat Struct Mol Biol* **23**, 656-662
11. Yowler, B. C., Kensinger, R. D., and Schengrund, C. L. (2002) Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. *J. Biol. Chem.* **277**, 32815-32819
12. Black, R. E., and Gunn, R. A. (1980) Hypersensitivity reactions associated with botulinal antitoxin. *Am J Med.* **69**, 567-570. doi: 10.1016/0002-9343(1980)90469-90466.
13. Schussler, E., Sobel, J., Hsu, J., Yu, P., Meaney-Delman, D., Grammer, L. C., 3rd, and Nowak-Wegrzyn, A. (2017) Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review. *Clin Infect Dis.* **66**, S65-S72. doi: 10.1093/cid/cix1827.
14. Arnon, S. S., Schechter, R., Maslanka, S. E., Jewell, N. P., and Hatheway, C. L. (2006) Human botulism immune globulin for the treatment of infant botulism. *N Engl J Med* **354**, 462-471
15. Khouri, J. M., Motter, R. N., and Arnon, S. S. (2018) Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. *Vaccine.* **36**, 2041-2048. doi: 10.1016/j.vaccine.2018.2002.2042.
16. Nayak, S. U., Griffiss, J. M., McKenzie, R., Fuchs, E. J., Jurao, R. A., An, A. T., Ahene, A., Tomic, M., Hendrix, C. W., and Zenilman, J. M. (2014) Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. *Antimicrob Agents Chemother.* **58**, 5047-5053. doi: 10.1128/AAC.02830-02814.

17. Rasetti-Escargueil, C., Avril, A., Miethe, S., Mazuet, C., Derman, Y., Selby, K., Thullier, P., Pelat, T., Urbain, R., Fontayne, A., Korkeala, H., Sesardic, D., Hust, M., and Popoff, M. R. (2017) The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies. *Toxins (Basel)* **9**, 309. doi: 10.3390/toxins9100309
18. Lou, J., and Marks, J. D. (2018) Botulinum Neurotoxins (BoNTs)-Antibody and Vaccine. *Toxins (Basel)*. **10(12)**. toxins10120495. doi: 10.10123390/toxins10120495.
19. Fan, Y., Garcia-Rodriguez, C., Lou, J., Wen, W., Conrad, F., Zhai, W., Smith, T. J., Smith, L. A., and Marks, J. D. (2017) A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. *PLoS One* **12**, e0174187
20. Garcia-Rodriguez, C., Razai, A., Geren, I. N., Lou, J., Conrad, F., Wen, W. H., Farr-Jones, S., Smith, T. J., Brown, J. L., Skerry, J. C., Smith, L. A., and Marks, J. D. (2018) A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. *Toxins (Basel)* **10**, doi: 10.3390/toxins10030105
21. Nowakowski, A., Wang, C., Powers, D. B., Amersdorfer, P., Smith, T. J., Montgomery, V. A., Sheridan, R., Blake, R., Smith, L. A., and Marks, J. D. (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. *Proc. Ntl. Acad. Sci. (USA)* **99**, 11346-11350
22. Lou, J., Wen, W., Conrad, F., Meng, Q., Dong, J., Sun, Z., Garcia-Rodriguez, C., Farr-Jones, S., Cheng, L. W., Henderson, T. D., Brown, J. L., Smith, T. J., Smith, L. A., Cormier, A., and Marks, J. D. (2018) A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. *Toxins (Basel)* **10**, 84. doi: 10.3390/toxins10020084
23. Mazuet, C., Dano, J., Popoff, M. R., Creminon, C., and Volland, H. (2010) Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. *PLoS One* **5**, e12416
24. Prigent, J., Mazuet, C., Boquet, D., Lamourette, P., Volland, H., Popoff, M. R., Creminon, C., and Simon, S. (2010) Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A. *PLoS One* **5**, e13245
25. Brier, S., Le Mignon, M., Jain, K., Lebrun, C., Peurois, F., Kellenberger, C., Bordas-Le Floch, V., Mascarell, L., Nony, E., and Moingeon, P. (2018) Characterization of epitope specificities of reference antibodies used for the quantification of the birch pollen allergen Bet v 1. *Allergy*. **73**, 1032-1040. doi: 10.1111/all.13364.

26. Brier, S., Lemaire, D., DeBonis, S., Kozielski, F., and Forest, E. (2006) Use of hydrogen/deuterium exchange mass spectrometry and mutagenesis as a tool to identify the binding region of inhibitors targeting the human mitotic kinesin Eg5. *Rapid Commun Mass Spectrom* **20**, 456-462. doi: 10.1002/rcm.2329.
27. Volland, H., Lamourette, P., Nevers, M. C., Mazuet, C., Ezan, E., Neuburger, L. M., Popoff, M., and Creminon, C. (2008) A sensitive sandwich enzyme immunoassay for free or complexed *Clostridium botulinum* neurotoxin type A. *J Immunol Methods* **330**, 120-129
28. Tavallaie, M., Chenal, A., Gillet, D., Pereira, Y., Manich, M., Gibert, M., Raffestin, S., Popoff, M. R., and Marvaud, J. C. (2004) Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. *FEBS Lett.* **572**, 299-306
29. Couesnon, A., Molgo, J., Connan, C., and Popoff, M. R. (2012) Preferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestine. *PLoS Pathog* **8**, e1002583
30. Burns, J. R., Lambert, G. S., and Baldwin, M. R. (2017) Insights into the Mechanisms by Which Clostridial Neurotoxins Discriminate between Gangliosides. *Biochemistry.* **56**, 2571-2583. doi: 10.1021/acs.biochem.2576b01246.
31. Karalewitz, A. P., Kroken, A. R., Fu, Z., Baldwin, M. R., Kim, J. J., and Barbieri, J. T. (2010) Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. *Biochemistry* **49**, 8117-8126
32. Strotmeier, J., Gu, S., Jutzi, S., Mahrhold, S., Zhou, J., Pich, A., Eichner, T., Bigalke, H., Rummel, A., Jin, R., and Binz, T. (2011) The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. *Mol Microbiol* **81**, 143-156
33. Malizio, C. J., Goodnough, M. C., and Johnson, E. A. (2000) Purification of *Clostridium botulinum* type A neurotoxin. *Methods Mol Biol* **145**, 27-39
34. Rasetti-Escargueil, C., Avril, A., Chahboun, S., Tierney, R., Bak, N., Miethe, S., Mazuet, C., Popoff, M. R., Thullier, P., Hust, M., Pelat, T., and Sesardic, D. (2015) Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. *Mabs* **7**, 1161-1177
35. Masson, G. R., Burke, J. E., Ahn, N. G., Anand, G. S., Borchers, C., Brier, S., Bou-Assaf, G. M., Engen, J. R., Englander, S. W., Faber, J., Garlish, R., Griffin, P. R., Gross, M. L., Guttman, M., Hamuro, Y., Heck, A. J. R., Houde, D., Iacob, R. E., Jorgensen, T. J. D.,

- Kaltashov, I. A., Klinman, J. P., Konermann, L., Man, P., Mayne, L., Pascal, B. D., Reichmann, D., Skehel, M., Snijder, J., Strutzenberg, T. S., Underbakke, E. S., Wagner, C., Wales, T. E., Walters, B. T., Weis, D. D., Wilson, D. J., Wintrode, P. L., Zhang, Z., Zheng, J., Schriemer, D. C., and Rand, K. D. (2019) Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. *Nat Methods*. **16**, 595-602. doi: 10.1038/s41592-41019-40459-y.
36. Hourdel, V., Volant, S., O'Brien, D. P., Chenal, A., Chamot-Rooke, J., Dillies, M. A., and Brier, S. (2016) MEMHDX: an interactive tool to expedite the statistical validation and visualization of large HDX-MS datasets. *Bioinformatics*. **32**, 3413-3419. doi: 10.1093/bioinformatics/btw3420. Epub 2016 Jul 3413.
37. Guttman, M., Weis, D. D., Engen, J. R., and Lee, K. K. (2013) Analysis of overlapped and noisy hydrogen/deuterium exchange mass spectra. *J Am Soc Mass Spectrom*. **24**, 1906-1912. doi: 10.1007/s13361-13013-10727-13365.
38. Pellett, S., Tepp, W. H., Whitemarsh, R. C., Bradshaw, M., and Johnson, E. A. (2015) In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5. *Toxicon* **107**, 37-42
39. Whitemarsh, R. C., Tepp, W. H., Bradshaw, M., Lin, G., Pier, C. L., Scherf, J. M., Johnson, E. A., and Pellett, S. (2013) Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. *Infect Immun*. **81**, 3894-3902. doi: 10.1128/IAI.00536-00513.
40. Stenmark, P., Dupuy, J., Imamura, A., Kiso, M., and Stevens, R. C. (2008) Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. *PLoS Pathog* **4**, e1000129
41. Guttman, M., Wales, T. E., Whittington, D., Engen, J. R., Brown, J. M., and Lee, K. K. (2016) Tuning a High Transmission Ion Guide to Prevent Gas-Phase Proton Exchange During H/D Exchange MS Analysis. *J Am Soc Mass Spectrom*. **27**, 662-668. doi: 10.1007/s13361-13015-11330-13368.
42. Mukherjee, J., Tremblay, J. M., Leysath, C. E., Ofori, K., Baldwin, K., Feng, X., Bedenice, D., Webb, R. P., Wright, P. M., Smith, L. A., Tzipori, S., and Shoemaker, C. B. (2012) A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. *PLoS One* **7**, e29941. doi: 10.1371/journal.pone.0029941.

43. Yao, G., Lam, K. H., Weisemann, J., Peng, L., Krez, N., Perry, K., Shoemaker, C. B., Dong, M., Rummel, A., and Jin, R. (2017) A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding. *Sci Rep* **7**, 7438
44. Garcia-Rodriguez, C., Geren, I. N., Lou, J., Conrad, F., Forsyth, C., Wen, W., Chakraborti, S., Zao, H., Manzanarez, G., Smith, T. J., Brown, J., Tepp, W. H., Liu, N., Wijesuriya, S., Tomic, M. T., Johnson, E. A., Smith, L. A., and Marks, J. D. (2011) Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. *Protein Eng Des Sel.* **24**, 321-331. doi: 10.1093/protein/gzq111.
45. Garcia-Rodriguez, C., Levy, R., Arndt, J. W., Forsyth, C. M., Razai, A., Lou, J., Geren, I., Stevens, R. C., and Marks, J. D. (2007) Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. *Nat Biotechnol.* **25**, 107-116. doi: 10.1038/nbt1269.
46. Dong, M., Yeh, F., Tepp, W. H., Dean, C., Johnson, E. A., Janz, R., and Chapman, E. R. (2006) SV2 Is the Protein Receptor for Botulinum Neurotoxin A. *Science* **312**, 592-596
47. Kozaki, S., Kamata, Y., Watarai, S., Nishiki, T., and Mochida, S. (1998) Ganglioside GT1b as a complementary receptor component for *Clostridium botulinum* neurotoxins. *Microbiol. Pathol.* **25**, 91-99
48. Yowler, B. C., and Schengrund, C. L. (2004) Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. *Biochemistry* **43**, 9725-9731
49. Hifumi, T., Yamamoto, A., Ato, M., Sawabe, K., Morokuma, K., Morine, N., Kondo, Y., Noda, E., Sakai, A., Takahashi, J., and Umezawa, K. (2017) Clinical Serum Therapy: Benefits, Cautions, and Potential Applications. *Keio J Med.* **66**, 57-64. doi: 10.2302/kjm.2016-0017-IR.
50. Thanongsaksrikul, J., and Chaicumpa, W. (2011) Botulinum neurotoxins and botulism: a novel therapeutic approach. *Toxins (Basel).* **3**, 469-488. doi: 10.3390/toxins3050469. Epub 3052011 May 3050413.
51. Hill, S. E., Iqbal, R., Cadiz, C. L., and Le, J. (2013) Foodborne botulism treated with heptavalent botulism antitoxin. *Ann Pharmacother.* **47**, e12. doi: 10.1345/aph.1341R1646.
52. Hibbs, R. G., Weber, J. T., Corwin, A., Allos, B. M., Abd el Rehim, M. S., Sharkawy, S. E., Sarn, J. E., and McKee, K. T., Jr. (1996) Experience with the use of an investigational F(ab')₂ heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. *Clin Infect Dis* **23**, 337-340

53. Yu, P. A., Lin, N. H., Mahon, B. E., Sobel, J., Yu, Y., Mody, R. K., Gu, W., Clements, J., Kim, H. J., and Rao, A. K. (2017) Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin. *Clin Infect Dis.* **66**, S57-S64. doi: 10.1093/cid/cix1816.
54. Marks, J. D. (2004) Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. *Mov Disord* **19 Suppl 8**, S101-108
55. Carter, A. T., and Peck, M. W. (2015) Genomes, neurotoxins and biology of *Clostridium botulinum* Group I and Group II. *Res Microbiol* **166**, 303-317
56. Mazuet, C., Legeay, C., Sautereau, J., Ma, L., Bouchier, C., Bouvet, P., and Popoff, M. R. (2016) Diversity of Group I and II *Clostridium botulinum* Strains from France Including Recently Identified Subtypes. *Genome Biol Evol* **8**, 1643-1660
57. Williamson, C. H., Sahl, J. W., Smith, T. J., Xie, G., Foley, B. T., Smith, L. A., Fernandez, R. A., Lindstrom, M., Korkeala, H., Keim, P., Foster, J., and Hill, K. (2016) Comparative genomic analyses reveal broad diversity in botulinum-toxin-producing Clostridia. *BMC Genomics* **17**, 180

FIGURE LEGENDS

Figure 1 | Effects of TA12 binding on the deuterium uptake behavior of HcA1. **A**, The fractional uptake difference plot was generated for each peptide and at each time point by subtracting the deuterium uptake values in the TA12-unbound from those in the bound state. Positive numbers indicate TA12-induced protection (regions 1, 2, 4, 5 and 6) while negative values indicate an increase in solvent accessibility (region 3). The six regions displaying statistically significant changes of deuterium uptake upon TA12 binding (Wald test, $p < 0.05$) are highlighted in gray. Each dot corresponds to an average of three independent replicates. **B**, Mapping of the HDX-MS results obtained after 60 min labeling onto the cartoon and surface representations of HcA1 (pdb # 2NZ9). The largest reductions of deuterium uptake mainly occur within loops (regions 2, 4 and 5) located at the interface between the N-terminal lectin subdomain (H_{CN}) and the C-terminal trefoil subdomain (H_{CC}) whereas changes in dynamics are observed in H_{CN} only. “No change” refers to regions of HcA1 that show no statistically significant uptake difference between states during the time scale of the experiment. **C**, Mass spectra and deuterium uptake plot of peptide 1017-1035 that displays a bimodal isotopic pattern (EX1) in the presence of TA12. The EX1 behavior is characterized by an increase in the peak width due to the overlap of two distinct isotopic distributions corresponding to the low (red) and high (green) m/z populations. The center of these two distributions (blue, mix m/z) was used to generate the fractional uptake difference values for peptide 1017-1035 (panel A).

Figure 2 | TA12 blocks BoNT/A1 binding to SV2C-LD by targeting a common area on HcA1. **A**, Effects of SV2C-LD binding on the deuterium uptake behavior of HcA1. The Fractional uptake difference plot was generated for each peptide and at each time point by subtracting the uptake values measured in the SV2C-LD unbound-state from those in the bound state. Positive numbers indicate SV2C-LD induced protection (regions 1, 2, and 3). Regions displaying statistically significant changes of deuterium uptake upon SV2C-LD binding (Wald test, $p < 0.05$) are highlighted in gray. Each dot corresponds to an average of three independent replicates. **B**, Mapping of the HDX-MS results obtained after 60 min labeling onto the surface representation of HcA1 (pdb # 2NZ9). As observed with TA12, the largest reduction in deuterium uptake occurs within region 2 (i.e., 1145-1154 corresponding to region 5 in **Figure 1A, 1B**). The position of the SV2C-LD binding site identified by X-ray crystallography is also reported (magenta). The HcA1 residues in direct interaction with SV2C-LD are indicated. “No change” refers to regions of BoNT/A1 that show no statistically significant uptake difference

between states during the time scale of the experiment. **C**, Inhibition of H_CA1 binding to SV2C-LD by mAb TA12. H_CA1 (200 pmol) was preincubated with or without TA12 for 15 min at room temperature (Input) and then incubated with immobilized SV2C-LD on glutathione-Sepharose 4B beads for 90 min at 4°C. Bound H_CA1 was detected by 10% SDS-PAGE analysis after Coomassie blue staining. Load input volumes on gel were 1:10 of the total input volumes. TA12 was dissociated in heavy and light chains. A representative figure of 4 is shown.

Figure 3 | Effects of TA12 on the binding of the GT1b ganglioside. **A**, Structure of the H_CA1:GT1b complex (pdb # 2VU9) showing the position of the GT1b-binding site relative to the HDX-MS defined TA12 epitope. GT1b is shown as green sticks. A close-up view of the GT1b-binding interface is shown on the right side, where the position of residues Y1117 and F1252 involved in the coordination of GT1b are reported. The GT1b sialic acid 5 (Sia5) and galactose 4 (Gal4) hydrogen bonded respectively to Y1117 and F1252 are also indicated. The variations in deuterium uptake imposed by TA12 binding on H_CA1 are colored as in Figure 1. **B**, TA12 inhibition of H_CA1 binding to GT1b. H_CA1 (10 nM) was preincubated with or without increasing concentration of TA12 for 15 min at room temperature and then exposed to GT1b coated on 96-well plate (1 µg/well). Bound H_CA1 to GT1b was detected with rabbit anti-H_CA1 antibodies and HRP-goat anti-rabbit IgG. Representative experiment in triplicate is shown. TA12 128 nM and above completely prevent the binding of H_CA1 (10 nM) to GT1b.

Figure 4 | TA12 binds H_CA1 on the face opposite occupied by both ciA-C2 and the BoNT/A1-neutralizing therapeutic human monoclonal antibody CR1. Superposition of the structures of the H_CA1:ciA-C2 (pdb # 5L21), H_CA1:CR1 (pdb # 2NYY), H_CA1:GT1b (pdb # 2VU9) and H_CA1:gSV2C (pdb # 5JLV) complexes. GT1b and the N559-glycan of gSV2C are shown as green and cyan sticks respectively. CiA-C2 (dark red) partially occupies the binding site on H_CA1 of both the N-glycan (N559) and the peptide moieties of gSV2C, thereby interfering directly with gSV2C (cyan) binding to H_CA1. The region of H_CA1 containing critical residues for gSV2C binding (i.e., T1145 and T1146) and targeted by ciA-C2 is indicated by a black box. The BoNT/A1-neutralizing CR1 antibody (ribbon representation, gold) directly targets the gSV2C N599-glycan binding site on H_CA1 without competing with the gSV2C peptide binding site (black box). The variable region in the CR1 light chain overlaps almost completely with the ciA-C2 binding areas containing the gSV2C N599-glycan interaction site. The HDX-defined TA12 epitope (see color code in Figure 1) occupies the gSV2C peptide binding site targeted by ciA-C2 (black box), causing direct interferences with the peptide

moieties of gSV2C. In contrast to both ciA-C2 and CR1, TA12 does not affect the gSV2C glycan binding region but recognize a region of the GT1b-binding site. Thus, TA12 partially impaired H_cA1 binding to GT1b (Fig. 3B). The position of the TA12 epitope relative to the ciA-C2, CR1 and gSV2C binding sites is better visualized using the H_cA1 surface representation shown on the right side. TA12 shares a common binding interface with ciA-C2 but mainly occupies the face opposite on H_cA1 to both ciA-C2 and CR1 (black circle). The position of the N1006 residue identified as important for TA12 binding is indicated.

Table 1. Neutralization activity of TA12 mAb with BoNT/A subtypes

TA12 mAb quantity (ng/mouse)	0	10,000	2,500	1,000	250	25	2.5	mAb quantity (ng/mouse) yielding 50% neutralization
BoNT/A1	6/6	0/2	/	0/4	1/7	4/10	6/6	2.5<25
BoNT/A2*	9/9	/	0/9	/	6/9	9/9	/	250
BoNT/A3*	9/9	/	0/9	/	0/9	6/9	/	25<250
BoNT/A5	6/6	5/8	4/4	8/8	5/5	2/2	/	1,000<10,000
BoNT/A7	6/6	1/6	5/6	5/8	8/8	2/2	/	250<1,000

mAb neutralization activity was determined using the mouse protection assay with estimated 5 MLD₅₀/mL of BoNT/A subtype and serial dilutions of mAb. 5 estimated MLD₅₀/mouse were incubated with 2.5 to 10,000 ng of TA12 mAb for 30 min at room temperature and the mixture (0.5 mL) was injected intraperitoneally into each mouse.

Results are expressed as the number of dead mice versus the total number of mice.

*Data from (23).

Table 2. Binding affinities of mAb TA12 with BoNT/A subtypes H_C

BoNT/A H _C	Amino acid identity ^a (%)	k _{on} (1/Ms)	k _{off} (1/s)	K _D (pM)
H _C A1	-	3.01 10 ⁵	7.1 10 ⁻⁶	23.6
H _C A2	87.0	6.96 10 ⁵	7.74 10 ⁻⁵	111
H _C A3	86.58	1.13 10 ⁶	6.58 10 ⁻⁵	58.1
H _C A4	91.76	2.13 10 ⁵	5.91 10 ⁻⁴	2780
H _C A5	94.11	7.95 10 ⁵	7.55 10 ⁻⁴	949
H _C A7	91.76	2.83 10 ⁵	5.94 10 ⁻⁴	2100
H _C A1 R1156M		4.79 10 ⁵	1.47 10 ⁻⁵	30.7
H _C A1 V1143I/M1144V		6.42 10 ⁵	5.63 10 ⁻⁶	8.77
H _C A1 V1143I/M1144V/R1156M		4.09 10 ⁵	4.61 10 ⁻⁵	113
H _C A1 N1006A		1.88 10 ⁵	1.27 10 ⁻³	6755

^a Amino acid identity between H_CA1 and the other H_CA subtypes

Figure 1

849 **Figure 2**
850

852 **Figure 3**

853

A

B

854

855 **Figure 4**
856

857